

TFW



Docket No. PRD-26 CIP

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : De Corte, B. et al.

Serial No. : 10/782,060

Art Unit: 1646

Filed : February 18, 2004

Examiner: Not yet assigned

For : PIPERIDINYL TARGETING COMPOUNDS THAT SELECTIVELY  
BIND INTEGRINS

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

June 14, 2004  
(Date of Deposit)

Myra H. McCormack  
(Name of applicant, assignee, or Registered Representative)

Myra McCormack  
(Signature)

June 14, 2004  
(Date of Signature)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Statement in Accordance with §1.97(e) (attached); or

☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with \$1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in \$1.17(p).

☐ In accordance with \$1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with \$1.97(e) as set forth below and the fee of \$180.00 as set forth in \$1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not

enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i)).

☒ There are no listed references which are not in the English language.


☐ The relevance of those listed references which are not in the English language is as follows:

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD26CIP/MHM. This form is submitted in triplicate.

Respectfully submitted,

  
Myra H. McCormack  
Reg. No. 36,602  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-6932  
DATED: June 14, 2004



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 4

Application Number	10/782/060
Filing Date	February 18, 2004
First Named Inventor	DeCorte, B.
Group Art Unit	1646
Examiner Name	Not yet assigned
Attorney Docket Number	PRD-26 CIP

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			
		4,289,772		Campbell, S. et al.	09-15-1981	
		6,211,191	B1	Meissner, R.S. et al.	04-03-2001	
		5,919,792	B1	Duggan et al	07-06-1999	
		5,855,866		Thorpe et al	01-05-1999	
		6,342,219		Thorpe et al	01-29-2002	
		5,902,795		Toole et al	05-11-1999	
		5,762,918		Thorpe	06-09-1998	
		5,474,765		Thorpe	12-12-1995	
		2002/0016625	A1	Falotico et al	02-07-2002	

**FOREIGN PATENT DOCUMENTS**


Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	KindCode <sup>5</sup>				
		WO	9409029		Merck and Co., Inc.	04-28-1994		
		WO	99/31061	A1	Merck and Co., Inc.	06-24-1999		
		WO	00/72801	A2	Merck and Co., Inc.	12-07-2000		
		WO	01/96334	A2	Pharmacia Corporation	12-20-2001		
		WO	01/23376	A1	Ortho-McNeil Pharmaceutical, Inc.	04-05-2001		
		WO	00/35887	A2	Du Pont Pharmaceuticals Company	06-22-2000		
		WO	00/35492	A2	Du Pont Pharmaceuticals Company	06-22-2000		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

<i>Application Number</i>	10/782/060
<i>Filing Date</i>	February 18, 2004
<i>First Named Inventor</i>	DeCorte, B.
<i>Group Art Unit</i>	1646
<i>Examiner Name</i>	Not yet assigned
<i>Attorney Docket Number</i>	PRD-26 CIP

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 4

Application Number	10/782/060
Filing Date	February 18, 2004
First Named Inventor	DeCorte, B.
Group Art Unit	1646
Examiner Name	Not yet assigned
Attorney Docket Number	PRD-26 CIP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		KATANO, K. et al: "Tetrahydrothienopyridine derivatives as novel GPIIb/IIIa antagonists". Bioorganic & Medicinal Chemistry Letters (1996), 6(21), 2601-2606.	
		KLEIN, S.I. et al: "Design of a New Class of Orally Active Fibrinogen Receptor Antagonists". Journal of Medicinal Chemistry (1998), 41(14), 2492-2502.	
		GRUMEL, V. et al: "Synthesis of Substituted Oxazolo '4,5-b'pyridine Derivatives". Heterocycles (2001), 55(7), 1329-1345.	
		FISHER, M.J. et al: "Fused Bicyclic Gly-Asp-beta-tum Mimics with Potent Affinity for GPIIb-IIIa. Exploration of the Arginine Isostere". Bioorganic & Medicinal Chemistry Letters (2000), 10(4), 385-389.	
		LAWSON, E.C. et al: "1,2,4-Triazolo '4,3-alpyridine as a Novel, Constrained Template for Fibrinogen Receptor (GPIIb/IIIa) Antagonists: Bioorganic & Medicinal Chemistry Letters (2001), 11(19), 2619-2622.	
		SU, T. et al: "Fibrinogen Receptor (GPIIb-IIIa) Antagonists Derived From 5,6-Bicyclic Templates. Amidinoindoles, Amidinoindazoles, and Amidinobenzofurans Containing the N-Alpha-Sulfonamide Carboxylic Acid Function as Potent Platelet Aggregation Inhibitors". Journal of Medicinal Chemistry, American Chemical Society. Washington, U.S., vol.40, no.26, 1997, pages 4308-4318.	
		VARON, D. et al: "Inhibition of Integrin-Mediated Platelet Aggregation, Fibrinogen-Binding, and Interactions with Extracellular Matrix by Nonpeptidic Mimetics of Arg-Gly-Asp". Thrombosis and Haemostasis, Stutthard, DE vol. 70, no.6, 1993, pages 1030-1036.	
		VALERIE, A. et al. "2,4-Diamino-6,7-dimethoxyquinazolines, 2. 2-(4-Carbamoylpiperidino) Derivatives as alpha1-Adrenoceptor Antagonists and Antihypertensive Agents". Journal of Medicinal Chemistry, American Chemical Society. Washington, U.S. vol.30, 1987, pages 999-1003.	
		ISHIHARA, Y. et al. "Regioselective Friedel-Crafts Acylation of 2,3,4,5-Tetrahydro-1H-2-Be Nzapine and Related Nitrogen Heterocycles" Journal of the Chemical Society, Perkin Transactions 1, Chemical Society. Letchworth, GB, vol. 20, 1994, pages 2993-2999.	
		SAMANEN, J. et al. "Vascular Indications for Integrin Alphav Antagonists". Current Pharmaceutical Design, Bentham Science Publishers, Schiphol, NL, vol. 3, 1997, pgs. 545-584.	
		Amon, et al., Monoclonal Antibodies for Immunotargeting of Drugs In Cancer Therapy, Monoclonal Antibodies and Cancer Therapy, Reisfeld, et al. (eds.), pp. 243-256 (Alan R. Liss, Inc. 1985)	
		Brooks et al., Cell, 1994, 79, 1157-1164	
		de Groot FM, et al, "Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug, Mol. Can Ther. Sept. 2002, (11) pp. 901-911	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Substitute for form 1449/APTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary) <b>Sheet 4 of 4</b>	<b>Application Number</b>	10/782/060
	<b>Filing Date</b>	February 18, 2004
	<b>First Named Inventor</b>	DeCorte, B.
	<b>Group Art Unit</b>	1646
	<b>Examiner Name</b>	Not yet assigned
	<b>Attorney Docket Number</b>	PRD-26 CIP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		G.G. Bishop, "Selective $\alpha\beta 3$ -Receptor Blockade Reduces Macrophase Infiltration and Restenosis After Balloon angioplasty in the Atherosclerotic Rabbit", <i>Circulation</i> , April 10, 2001, pp.1906-1911	
		F.A.L.M. Eskens, "Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins $\alpha\beta 3$ and $\alpha\beta 5$ in patients with advanced solid tumors", <i>European Journal of Cancer</i> , 39, (2003), pp. 917-926	
		Hellstrom, et al., <i>Antibodies for Drug Delivery, Controlled Drug Delivery (2<sup>nd</sup> Ed.)</i> Robinson, et al. (eds), pp. 623-53 (Marcel Dekker, Inc. 1987)	
		Hood, J.D., et al, <i>Tumor Regression by Targeted Gene Delivery to the Neovasculature</i> , <i>Science</i> , 2002, 28 June, 296, 2404-2407	
		R.O. Hynes, "A reevaluation of integrins as regulators of angiogenesis", <i>Nature Medicine</i> , Vol. 8, No. 9, Sept. 2002, pp. 918-921.	
		W.J. Hoekstra, <i>Current Medicinal Chemistry</i> , 1998, 5, 195	
		<i>International J. Pharm.</i> , 1986, 33, 201-217	
		Xiao-Zhu Huang, et al., <i>Inactivation of the Integrin <math>\beta 6</math> Subunit Gene Reveals a Role of Epithelial Integrins in Regulating Inflammation in the Lungs and Skin</i> , <i>Journal of Cell Biology</i> , 1996, 133, 921-28	
		Melpo Christofidow-Solomindou, et al., <i>Expression and Function of Endothelial Cell on Integrin Receptors in Wound-Induced Human Angiogenesis in Human Skin/SCID 25 Mice Chimeras</i> , <i>American Journal of Pathology</i> , 1997, 151, 975-83	
		M.C. Friedlander, et al., <i>Science</i> , 1995, 270, 1500-1502	
		Kerr, J.S., "The alpha v integrin antagonists as novel anticancer agents: an update", <i>Expert Opin Investg Drugs</i> , 2002 Dec; 11(12):1765-74	
		R.M. Lafrenie, "Involvement of Integrin $\alpha\beta 3$ - in the Pathogenesis of Human Immunodeficiency Virus Type 1 Infection in Monocytes", <i>Virology</i> 297, 2002, pp. 31-38	
		S.A. Mousa, <i>Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications</i> , <i>Curr Opin. Chem. Biol.</i> Aug. 2002; 6(4), pp.534-541	
		S.A. Mousa, et al., <i>Emerging Therapeutic Targets</i> , 2000, 4, (2), 143-153	
		S.A. Mousa, et al., <i>Exp. Opin. Thera. Patents</i> , 1999, 9 (9), 1237-1248	
		S.A. Mousa, et al., <i><math>\alpha v</math> Vitronectin Receptors in Vascular-Mediated Disorders</i> , <i>Medicinal Research Reviews</i> , Vol. 23, No. 2, 190-199	
		Mehta et al. ( <i>Biochem J.</i> , 1998, 330, 861)	
		<i>J Pharm. Sci.</i> , 1977 (Jan), 66, 1, 1	
		S.B. Rodan and G.A. Rodan, <i>Integrin Function In Osteoclasts</i> , <i>Journal of Endocrinology</i> , 1997, 154:S47-S56	
		Ross, R., <i>Nature</i> , 1993, 362, 801-809	
		C.M. Storgard, et al, <i>Decreased Angiogenesis and Arthritic Disease in Rabbits Treated with an <math>\alpha\beta</math> Antagonist</i> , <i>J. Clin. Invest.</i> , 1999, 103, 47-54	
		W. H. Miller, et al., <i>Drug Discovery Today</i> , 2000, 5(9), 397-407	
		Thorpe, <i>Antibody Carriers Of Cytotoxic Agents in Cancer Therapy: A Review</i> , <i>Monoclonal Antibodies '84: Biological and Clinical Applications</i> , Pinchera, et al. (eds.), pp. 475-506 (1985)	
		Yin, L. et al., "Correlation of cell apoptosis induction with expression of human beta 5 integrin on hematopoietic cells", <i>Zhonghua Xue Ye Xue Za Zhi</i> , Jan 2001, 22(1) pp. 13-16	
		H. Zhang et al., " $\beta 21$ -activated kinase 4 interacts with integrin $\alpha\beta 5$ -mediated cell migration", <i>The Journal of Cell Biology</i> , vol. 158, No. 7, September 30, 2002, pp. 1287-1297	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.